Skye Bioscience (SKYE) Assets (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Assets of $19.4 million for Q1 2026, down 70.03% year-over-year from $64.8 million in Q1 2025, and down 31.42% quarter-over-quarter from $28.3 million in Q4 2025.
Skye Bioscience (SKYE) Assets (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Assets for 15 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 70.03% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $19.4 million (down 70.03% YoY), while the FY2025 annual figure was $28.3 million, down 61.09% from the prior year.
- Assets eased to $19.4 million in Q1 2026 per SKYE's latest filing, from $28.3 million in the prior quarter.
- Across five years, Assets topped out at $94.8 million in Q1 2024 and bottomed at $2.2 million in Q2 2023.
- Historically, Assets has averaged $35.3 million across 5 years, with a median of $19.4 million in 2026.
- Annual changes were most pronounced in 2022 — Assets sank 75.45% — and 2024, when it jumped 3802.67%.
- Skye Bioscience's Assets stood at $9.1 million in 2022, then soared by 31.05% to $11.9 million in 2023, then soared by 509.39% to $72.8 million in 2024, then sank by 61.09% to $28.3 million in 2025, then plunged by 31.42% to $19.4 million in 2026.
- Business Quant data shows SKYE's Assets at $19.4 million in Q1 2026, $28.3 million in Q4 2025, and $41.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 19.82 Bn |
| 10 | Skye Bioscience | 10.72 Mn | 10.72 Mn | - | 11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.42 Mn |
| Dec 31, 2025 | 28.31 Mn |
| Sep 30, 2025 | 41.32 Mn |
| Jun 30, 2025 | 52.16 Mn |
| Mar 31, 2025 | 64.79 Mn |
| Dec 31, 2024 | 72.76 Mn |
| Sep 30, 2024 | 81.54 Mn |
| Jun 30, 2024 | 87.26 Mn |
| Mar 31, 2024 | 94.84 Mn |
| Dec 31, 2023 | 11.94 Mn |
| Sep 30, 2023 | 15.60 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2022 | 9.11 Mn |
| Sep 30, 2022 | 2.87 Mn |
| Jun 30, 2022 | 4.97 Mn |
| Mar 31, 2022 | 7.21 Mn |
| Dec 31, 2021 | 9.86 Mn |
| Sep 30, 2021 | 11.69 Mn |
| Jun 30, 2021 | 5.49 Mn |